Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

7 Dec 2011 11:26

RNS Number : 5181T
Credit Suisse Securities (Eur) Ltd
07 December 2011
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Credit Suisse Securities (Europe) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Evolution Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Evolution Group Plc

(d) Date dealing undertaken:

6-December-2011

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary shares

Purchases

75,000

0.820(GBP)

0.820(GBP)

Ordinary shares

Sales

75,000

0.820(GBP)

0.820(GBP)

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

Nature of dealing

Number of reference securities

Price per unit (GBP)

e.g. CFD

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Ordinary Shares

Swap

Increasing a short

500000

83.33

Ordinary Shares

Swap

Reducing a short

3265

82.91

Ordinary Shares

Swap

Reducing a short

1400

83.05

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

Date of disclosure:

7-Dec-2011

Contact name:

Liane Agostini/ Anthony Allen / Paul MacDonald

Telephone number:

0207 888 3599 / 5416 / 8548

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBBBDDUDGBGBR
Date   Source Headline
22nd Mar 20217:00 amRNSAppointment of Chief Business Officer
15th Mar 20219:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSUpdate on Data Safety Review - STAR COVID-19 trial
9th Mar 202111:35 amRNSHolding(s) in Company
8th Mar 20211:49 pmRNSHolding(s) in Company
5th Mar 20214:04 pmRNSHolding(s) in Company
5th Mar 20219:17 amRNSDirector dealing
3rd Mar 202112:10 pmRNSResult of General Meeting & Total Voting Rights
3rd Mar 20217:00 amRNSResult of Open Offer
26th Feb 20214:39 pmRNSHolding(s) in Company
17th Feb 20219:58 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSUpdate on patient recruitment
12th Feb 20217:00 amRNSPosting of Circular & Notice of GM
2nd Feb 20213:15 pmRNSPlacing and Open Offer to raise up to £11 million
22nd Jan 20217:00 amRNSPreclinical data on a new therapeutic target
21st Jan 20217:00 amRNSPositive pre-clinical data for lead asset SFX-01
19th Jan 20217:00 amRNSPatient recruitment update in STAR-COVID 19 trial
23rd Dec 20202:05 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:00 pmRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSHalf-year Report
27th Nov 20202:33 pmRNSHolding(s) in Company
27th Nov 20209:15 amRNSHolding(s) in Company
23rd Nov 20207:00 amRNSRecruitment of first patient in STAR trial
11th Nov 20207:00 amRNSComment on the COVID-19 vaccine announcement
6th Nov 20209:25 amRNSHolding(s) in Company
29th Oct 202011:55 amRNSHolding(s) in Company
29th Oct 20209:09 amRNSHolding(s) in Company
26th Oct 20203:00 pmRNSHolding(s) in Company
23rd Oct 20207:00 amRNSAll approvals received for STAR trial to commence
6th Oct 20207:00 amRNSGrant of options
24th Sep 20207:00 amRNSAppointment of Chief Executive Officer
15th Sep 20207:00 amRNSLicence agreement with Juvenescence
18th Aug 20203:30 pmRNSHolding(s) in Company
18th Aug 20203:25 pmRNSHolding(s) in Company
14th Aug 20204:41 pmRNSSecond Price Monitoring Extn
14th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20203:40 pmRNSHolding(s) in Company
24th Jul 20209:47 amRNSShare option exercise and issue of equity
17th Jul 202012:05 pmRNSHolding(s) in Company
17th Jul 202012:02 pmRNSHolding(s) in Company
16th Jul 20202:52 pmRNSResult of AGM
7th Jul 202011:13 amRNSShare option exercise and issue of equity
6th Jul 20207:00 amRNSShare option exercise and issue of equity
23rd Jun 202011:44 amRNSHolding(s) in Company
23rd Jun 202011:38 amRNSHolding(s) in Company
19th Jun 20207:00 amRNSNotice of AGM
17th Jun 20209:38 amRNSHolding(s) in Company
17th Jun 20209:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.